Small molecule
heart failure therapeutics
Clyde has performed a number of lead optimisation studies for pharma companies using hiPSC and adult cardiomyoctyes. Using the three-in-one assay, a comprehensive set of efficacy data can be generated to guide medicinal chemistry efforts during lead optimisation.
Clyde has been instrumental in several heat failure programes, especially in guiding the difficult path between efficacy and safety.
Gene therapy
heart failure therapeutics
Recently Clyde has been approached to develop an efficacy heart failure assay for gene therapies. Exploiting diseased hiPSC cardiomyocyte cell lines and chronic protocols, heart failure assays for gene therapies will be established.
Clyde’s links with the FDA will be beneficial in order for the assays to be approved by the regulatory agencies.
CellOPTIQ® generates human-relevant information from:
Heart Failure Assay – Omecamtiv
Applications for drug development
CLYDE supports all aspects of the drug discovery process, including: